Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
France Targets Shein, Temu With Fast-Fashion Fees 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Rejects Apple Trade Secret Theft Claims 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
SAN DIEGO, March 05, 2018 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2017 financial results after the close of U.S. financial markets on Monday, March 12, 2018. Kura Oncology’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 5196505. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Contacts
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
Kura Oncology, Inc.
(858) 500-8803
[email protected]
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
[email protected]
